Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS

J. H. Kempen, Kevin Frick, Douglas Jabs

Research output: Contribution to journalArticle

Abstract

Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based have probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective.

Original languageEnglish (US)
Pages (from-to)1199-1208
Number of pages10
JournalPharmacoEconomics
Volume19
Issue number12
StatePublished - 2001

Fingerprint

Cytomegalovirus
Cost-Benefit Analysis
Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Cytomegalovirus Retinitis
Costs and Cost Analysis
Health Care Costs
Morbidity
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS. / Kempen, J. H.; Frick, Kevin; Jabs, Douglas.

In: PharmacoEconomics, Vol. 19, No. 12, 2001, p. 1199-1208.

Research output: Contribution to journalArticle

@article{f2f009b85bff48aaa5ef5d0cdab14895,
title = "Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS",
abstract = "Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based have probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective.",
author = "Kempen, {J. H.} and Kevin Frick and Douglas Jabs",
year = "2001",
language = "English (US)",
volume = "19",
pages = "1199--1208",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "12",

}

TY - JOUR

T1 - Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS

AU - Kempen, J. H.

AU - Frick, Kevin

AU - Jabs, Douglas

PY - 2001

Y1 - 2001

N2 - Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based have probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective.

AB - Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based have probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective.

UR - http://www.scopus.com/inward/record.url?scp=0035695171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035695171&partnerID=8YFLogxK

M3 - Article

C2 - 11772155

AN - SCOPUS:0035695171

VL - 19

SP - 1199

EP - 1208

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 12

ER -